These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 30206306)

  • 1. COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
    Klupsch K; Baeriswyl V; Scholz R; Dannenberg J; Santimaria R; Senn D; Kage E; Zumsteg A; Attinger-Toller I; von der Bey U; König-Friedrich S; Dupuy F; Lembke W; Albani C; Wendelspiess S; Dinkel L; Saro D; Hepler RW; Laszlo GS; Gudgeon CJ; Bertschinger J; Brack S; Walter RB
    Leukemia; 2019 Mar; 33(3):805-808. PubMed ID: 30206306
    [No Abstract]   [Full Text] [Related]  

  • 2. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
    Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
    Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
    Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
    Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
    Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
    Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
    Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF
    PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel therapeutic bispecific format based on synthetic orthogonal heterodimers enables T cell activity against Acute myeloid leukemia.
    Burke A; Borot F; Du X; Churchill M; Ding J; Grass AM; DeSouza P; Ali AM; Mukherjee S
    Oncogene; 2023 Jan; 42(1):26-34. PubMed ID: 36357573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
    Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD33 directed bispecific antibodies in acute myeloid leukemia.
    Clark MC; Stein A
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.
    Aliperta R; Cartellieri M; Feldmann A; Arndt C; Koristka S; Michalk I; von Bonin M; Ehninger A; Bachmann J; Ehninger G; Bornhäuser M; Bachmann MP
    Blood Cancer J; 2015 Sep; 5(9):e348. PubMed ID: 26383821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approach.
    Yang C; Wang Y; Ge MH; Fu YJ; Hao R; Islam K; Huang P; Chen F; Sun J; Hong F; Naranmandura H
    Biomater Sci; 2019 Feb; 7(3):938-950. PubMed ID: 30519686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
    Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
    Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
    Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
    Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukaemia.
    Fasslrinner F; Arndt C; Koristka S; Feldmann A; Altmann H; von Bonin M; Schmitz M; Bornhäuser M; Bachmann M
    Br J Haematol; 2019 Sep; 186(5):735-740. PubMed ID: 31119728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells.
    Stamova S; Cartellieri M; Feldmann A; Bippes CC; Bartsch H; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Rieber EP; Bachmann M
    Leukemia; 2011 Jun; 25(6):1053-6. PubMed ID: 21415850
    [No Abstract]   [Full Text] [Related]  

  • 17. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
    Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
    Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells.
    Balaian L; Ball ED
    Leuk Res; 2001 Dec; 25(12):1115-25. PubMed ID: 11684286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
    Herrmann M; Krupka C; Deiser K; Brauchle B; Marcinek A; Ogrinc Wagner A; Rataj F; Mocikat R; Metzeler KH; Spiekermann K; Kobold S; Fenn NC; Hopfner KP; Subklewe M
    Blood; 2018 Dec; 132(23):2484-2494. PubMed ID: 30275109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of IL-12Rβ2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC-deficient mice.
    Ferretti E; Montagna D; Di Carlo E; Cocco C; Ribatti D; Ognio E; Sorrentino C; Lisini D; Bertaina A; Locatelli F; Pistoia V; Airoldi I
    Leukemia; 2012 Feb; 26(2):225-35. PubMed ID: 21844875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.